This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Sandoz Ag. Active years: 2015-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015-2017
Title: Alfred Rupprechter: Innovator in Therapeutic Protein Purification
Introduction
Alfred Rupprechter is a notable inventor based in Kundl, Austria. He has made significant contributions to the field of therapeutic applications through his innovative work on fusion proteins. With a total of 2 patents, Rupprechter's inventions focus on improving the efficacy and purity of therapeutic proteins.
Latest Patents
Rupprechter's latest patents include methods for the quantification of misfolded TNFR2:Fc. This invention is directed towards determining the relative amount of incorrectly disulphide bridged TNFR2:Fc in a sample. TNFR2:Fc is a fusion protein utilized in various therapeutic applications. Additionally, the invention encompasses a method for purifying TNFR2:Fc, which utilizes the quantification method to ascertain the percentage of misfolded proteins. The resulting TNFR2:Fc compositions obtained through this process are expected to enhance therapeutic outcomes.
Career Highlights
Rupprechter is currently associated with Sandoz AG, a leading global healthcare company. His work at Sandoz AG has allowed him to focus on the development of innovative solutions in the pharmaceutical industry. His expertise in protein purification and quantification has positioned him as a valuable asset in the field.
Collaborations
Rupprechter has collaborated with notable colleagues, including Michael Fuchs and Johann Holzmann. These collaborations have further enriched his research and development efforts, leading to advancements in therapeutic protein applications.
Conclusion
Alfred Rupprechter's contributions to the field of therapeutic proteins through his patents and work at Sandoz AG highlight his role as an innovator. His focus on improving the purity and efficacy of fusion proteins is paving the way for advancements in therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile